Incyte Corporation (INCY)
NASDAQ · Healthcare · Biotechnology
Incyte Corporation is a Healthcare company with a market capitalization of $22.73B and a trailing P/E ratio of 16.1.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | April 28, 2026 | $1.81 | $1.34 | +35.1% |
| Q4 2025 | February 10, 2026 | $1.80 | $1.92 | -6.3% |
| Q3 2025 | October 28, 2025 | $2.26 | $1.64 | +37.8% |
| Q2 2025 | July 29, 2025 | $1.57 | $1.47 | +6.8% |
| Q1 2025 | April 29, 2025 | $1.16 | $1.03 | +12.6% |
| Q4 2024 | February 10, 2025 | $1.43 | $1.55 | -7.7% |
Other Biotechnology Stocks
Frequently Asked Questions
What is Incyte Corporation's market cap?
As of June 29, 2026, Incyte Corporation (INCY) has a market capitalization of $22.73B.
What is Incyte Corporation's P/E ratio?
Incyte Corporation trades at a trailing price-to-earnings (P/E) ratio of 16.1. Its forward P/E is 14.6.
Does Incyte Corporation pay a dividend?
Incyte Corporation does not currently pay a dividend.
What sector is INCY in?
Incyte Corporation is in the Healthcare sector, specifically the Biotechnology industry.
What was Incyte Corporation's revenue?
In its latest reported fiscal year (ending December 31, 2025), Incyte Corporation reported revenue of $5.14B and net income of $1.29B.
Ask your own questions about INCY
Try mrmarket.ai freeData as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.